Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide - PubMed (original) (raw)

Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide

K Masuda et al. Diabetologia. 1995 Jan.

Abstract

In order to elucidate the direct effects of (+/-)-5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy) benzyl]-2,4-thiazolidinedione (Troglitazone), a newly-developed oral hypoglycaemic agent, on pancreatic beta-cell function, in vitro investigation of isolated rat pancreatic islets and a hamster beta-cell line (HIT cell) were performed. Troglitazone stimulates both glucose, and glibenclamide-induced insulin release at a concentration of 10(-6) mol/l in these cells but, conversely, inhibits insulin secretion at 10(-4) mol/l. Glucose uptake in HIT cells is similarly enhanced by 10(-6) mol/l Troglitazone, but is reduced in the presence of 10(-4) mol/l Troglitazone. However, a quantitative immunoblot analysis with a specific antibody for GLUT 2 glucose transporter revealed no significant change in GLUT 2 protein in HIT cells with 10(-6) mol/l Troglitazone. Specific binding of [3H]-glibenclamide to beta-cell membranes is replaced by Troglitazone in a non-competitive manner, but 10(-6) mol/l Troglitazone failed to eliminate ATP-sensitive K++ channel activity. These results suggest that Troglitazone has a putative non-competitive binding site at, or in the vicinity of, the sulphonylurea receptor in rat pancreatic islets and HIT cells and that the dual effect of Troglitazone on insulin secretory capacity is mediated through the modulation of glucose transport activity, possibly due to the modification of intrinsic activity in glucose transporter in pancreatic beta cells by this novel agent.

PubMed Disclaimer

Cited by

Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis.
Takahashi M, Shibasaki M, Echizen H, Kushiyama A. Takahashi M, et al. PLoS One. 2020 Jul 24;15(7):e0236603. doi: 10.1371/journal.pone.0236603. eCollection 2020. PLoS One. 2020. PMID: 32706828 Free PMC article.
The effects of Leptin and Adiponectin on Pdx1, Foxm1, and PPARγ Transcription in Rat Islets of Langerhans.
Mahmoodzadeh Sagheb M, Azarpira N, Mokhtary M, Hosseini SE, Yaghobi R. Mahmoodzadeh Sagheb M, et al. Hepat Mon. 2013 Jun 22;13(6):e9055. doi: 10.5812/hepatmon.9055. eCollection 2013. Hepat Mon. 2013. PMID: 24032047 Free PMC article.
In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion.
Eldor R, DeFronzo RA, Abdul-Ghani M. Eldor R, et al. Diabetes Care. 2013 Aug;36 Suppl 2(Suppl 2):S162-74. doi: 10.2337/dcS13-2003. Diabetes Care. 2013. PMID: 23882042 Free PMC article. Review. No abstract available.
Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes.
DeFronzo RA, Eldor R, Abdul-Ghani M. DeFronzo RA, et al. Diabetes Care. 2013 Aug;36 Suppl 2(Suppl 2):S127-38. doi: 10.2337/dcS13-2011. Diabetes Care. 2013. PMID: 23882037 Free PMC article. No abstract available.
Suppression effects of AICAR on insulin secretion involved in peroxisome proliferator-activated receptor gamma changes in INS-1 cells.
Guo H, Zhang XJ, Wang F, Wang Y, Shen Y, Zhao JJ, Gao L. Guo H, et al. J Endocrinol Invest. 2010 Jul-Aug;33(7):465-71. doi: 10.1007/BF03346626. Epub 2010 Jan 22. J Endocrinol Invest. 2010. PMID: 20101096

References

1. Nature. 1970 Aug 15;227(5259):680-5 - PubMed
1. J Biol Chem. 1987 Nov 25;262(33):15840-4 - PubMed
1. Diabetes. 1992 Jul;41(7):861-5 - PubMed
1. Diabetes. 1980 Jun;29(6):497-500 - PubMed
1. Endocr J. 1994 Apr;41(2):139-44 - PubMed

Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide - PubMed (original) (raw)